posted on 2020-11-30, 14:04authored byXizheng Sun, Reika Tokunaga, Yoko Nagai, Ryo Miyahara, Akihiro Kishimura, Shigeru Kawakami, Yoshiki Katayama, Takeshi Mori
We
have validated that ligand peptides designed from antigen peptides
could be used for targeting specific major histocompatibility complex
class I (MHC-I) molecules on the cell surface. To design the ligand
peptides, we used reported antigen peptides for each MHC-I molecule
with high binding affinity. From the crystal structure of the peptide/MHC-I
complexes, we determined a modifiable residue in the antigen peptides
and replaced this residue with a lysine with an ε-amine group
modified with functional molecules. The designed ligand peptides successfully
bound to cells expressing the corresponding MHC-I molecules via exchange
of peptides bound to MHC-I. We demonstrated that the peptide ligands
could be used to transport a protein or a liposome to cells expressing
the corresponding MHC-I. This strategy may be useful for targeted
delivery to cells overexpressing MHC-I, which have been observed in
autoimmune diseases.